Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 24,427	$ 14,949
Marketable securities		18,576
Accounts receivable	3,026	402
Insurance recovery (Note 13)		15,000
Clinical trial retainers	126	1,027
Other prepaid expenses and other current assets	356	229
Total current assets	27,935	50,183
Other assets		15
Total assets	27,935	50,198
Current liabilities:
Accounts payable	3,499	2,436
Accrued clinical trial costs and contract research	6,254	8,321
Other accrued liabilities	2,698	2,458
Loans payable, net of discount	3,254
Deferred revenue	1,658	395
Deferred research and development reimbursements	454	901
Estimated settlement liability (Note 13)		17,073
Other liabilities (Note 6)	300	540
Total current liabilities	18,117	32,124
Loans payable, net of current portion and discount	15,779	18,477
Deferred revenue	3,802	1,302
Deferred research and development reimbursements		222
PIPE Warrant liability (Note 7)	16,674	37,746
Other liabilities (Note 6)	790	1,090
Total liabilities	55,162	90,961
Stockholders' deficit:
Preferred stock, $.001 par value: 5,000 shares authorized at each of December 31, 2018 and 2017; no shares issued and outstanding at each of December 31, 2018 and 2017
Common stock, $.001 par value: 250,000 shares authorized at each of December 31, 2018 and December 31, 2017; 126,485 and 118,325 shares issued and outstanding as of December 31, 2018 and 2017, respectively	126	118
Additional paid-in capital	567,655	546,092
Accumulated other comprehensive income (loss)	1	(4)
Accumulated deficit	(595,009)	(586,969)
Total stockholders’ deficit	(27,227)	(40,763)
Total liabilities and stockholders’ deficit	$ 27,935	$ 50,198